Disease progression and recurrence are major barriers to surviving breast cancer. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron and DEK, cooperate to promote advanced disease through multi-pronged effects on β-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron over-expression in human disease stimulates β-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including β-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis, and fewer cells expressing cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion in vitro and in vivo. Mechanistically, Dek expression stimulated the production and secretion of Wnt Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms 
Introduction
Despite high survival rates for early stage breast cancer, it is still the second-leading cause of cancer-related deaths in the United States. This is due to the poor survival associated with late stage, invasive disease and treatment resistant breast cancers. Most new diagnoses are invasive cancers, which have poor survival rates 1 Therefore, it is important to identify proteins that predict disease relapse or progression and that also may be therapeutic targets.
Several reports identified the RON (Recepteur d'Origine Nantaise) receptor tyrosine kinase, a MET family member, as an important driver of breast tumorigenesis. RON is minimally expressed in normal breast epithelium but is highly expressed in approximately 50% of human breast cancers. 2 RON activation from overexpression has been implicated in driving metastasis and correlates with poor prognosis. 2, 3 Little is known about the molecular mechanisms through which RON promotes breast cancer proliferation and metastases. Recently, it was reported that RON activation leads to c-abl activation and PCNA localization to chromatin to drive proliferation. 4 RON also activates numerous cytoplasmic signaling pathways, including Ras/MAPK, PI3K, and β-catenin through direct phosphorylation, and regulates many downstream targets. [5] [6] [7] Here, we identify a novel nuclear effector of RON activation, the DEK oncogene.
DEK is a unique protein with no known paralogs or enzymatic function. 8 It is predominantly chromatin-bound and has been implicated in numerous processes including DNA repair, replication, transcriptional regulation, and mRNA splicing. [8] [9] [10] [11] [12] [13] [14] The role of DEK in these processes is unclear, but may be due to its histone chaperone and Su(var) activities that regulate chromatin organization. 15, 16 Many reports have shown that DEK can function as a cofactor for transcriptional regulation; however, DEK can both repress and activate transcription of target genes. For example, several reports have shown that DEK inhibits NFκB/p65/RelA transcriptional activity [17] [18] [19] , decreases hTERT expression in leukemias, 20 and can interact with PARP1 to restrict the accessibility of the transcription complexes to chromatin. 21 Other reports indicate that DEK can also activate transcription by interacting with several transcription factors including, C/EBPα during myeloid differentiation, 22 nuclear ecdysone receptor (EcR) in Drosophila, 16 and AP-2α in rat liver and human cell lines. 10 Interestingly, DEK can also be secreted and is an auto-antigen in patients with juvenile idiopathic arthritis and was detected in the urine of patients with bladder cancer. [23] [24] [25] Macrophages can secrete DEK and neighboring cells can internalize it in a heparan sulfate dependent process where it then completes its normal nuclear functions. 26 DEK is transcriptionally upregulated in several solid tumors and was initially discovered as a CAN (NUP214) fusion gene in acute myeloid leukemia. [27] [28] [29] [30] [31] [32] Transcriptional up-regulation is accomplished via the Rb/E2F pathway and steroid hormone signaling, but 6p22.3 amplifications have been noted. [32] [33] [34] [35] [36] Cell culture, murine chemical carcinogenesis, and xenograft tumor models indicate that DEK over-expression promotes proliferation. 29, 30, 32, 37 There are several possible molecular mechanisms for this DEKmediated proliferation, including up-regulation of ΔNp63α and, in the case of the DEK-NUP214 fusion, mTORC1 activity. 29, 30, 37, 38 Additional cell culture models implicate DEK in promoting cell invasion, in part due to β-catenin signaling. 29, 32 However, the oncogenic functions of DEK have not been tested in vivo using genetically engineered mouse models. Furthermore, the molecular mechanisms through which full-length DEK drives proliferation and β-catenin signaling in breast cancer are unknown.
Here, we crossed Dek −/− mice with the MMTV-Ron murine breast cancer model to determine the requirement for Dek during breast cancer initiation and progression. We report that Dek is a downstream target of activated Ron signaling such that the MMTV-Ron model recapitulates DEK over-expression observed in some human breast cancers. The loss of Dek delayed tumor growth and decreased lung metastases. We generated Dek proficient and deficient breast cancer cell lines from the murine tumors and found that reconstitution of Dek in knockout cells rescued cellular growth and invasive phenotypes in vitro. Importantly, we present new evidence that Dek expressing cells can drive the proliferation of cells within the microenvironment through stimulated expression and secretion of Wnt4, Wnt7b, and Wnt10b. Finally, we translate the observed oncogenic DEK activities, and the combination of RON and DEK activation, to human breast cancer using 3D cell culture models, tissue microarrays, and patient survival data. We propose that DEK drives tumor growth and progression, particularly in the context of RON receptor activation, via Wnt ligand production and subsequent activation of the β-catenin pathway.
Results

The MMTV-Ron mouse model recapitulates DEK over-expression observed in breast cancer
The MMTV-Ron mouse is an established malignant breast cancer model wherein Ron expression is controlled by the MMTV mammary-specific promoter. Mice begin to develop tumors at 4-5 months of age with a high prevalence of lung metastases. 3 Western blot analysis of primary tumors from MMTV-Ron mice compared to normal murine mammary gland tissue revealed Dek up-regulation in tumors ( Figure 1A) . Furthermore, western blot analysis of mammary epithelial cells (MECs) isolated from a non-transgenic (WT) and a non-tumor bearing MMTV-Ron transgenic mouse also revealed Dek upregulation in the transgenic mammary gland ( Figure 1B ). To determine whether Ron activation specifically induced Dek expression, R7 mammary tumor cells previously isolated from a MMTV-Ron tumor were treated with the Ron ligand, hepatocyte growth factor-like protein (HGFL; Figure S1 ). 3, 39 Ron activation with HGFL resulted in increased Dek mRNA and protein ( Figure 1C and 1D) , indicating that Dek is a downstream target of Ron. These findings show that the MMTV-Ron (Ron tg ) model is appropriate for studying the role of Dek overexpression during tumorigenesis in vivo.
The absence of Dek delays tumor development due to diminished proliferation
The Dek knockout allele was introduced into the MMTV-Ron mouse to generate Dek deficient (Ron tg Dek −/− ) mice. Ron tg Dek −/− mice were significantly delayed in palpable tumor development compared to Dek proficient Ron tg Dek +/+ controls (Figure 2A ). There were no significant differences in tumor incidence or in the number of tumors that eventually developed (Figure 2A and data not shown). We previously published that DEK depletion by shRNA in MDA-MB-468 human breast cancer cells results in smaller xenograft tumors associated with decreased tumor proliferation. 29 To determine if decreased proliferation accounted for the delayed tumor onset in Ron tg Dek −/− mammary glands, preneoplastic glands were analyzed for BrdU incorporation as a proliferation marker. Glands from Ron tg Dek −/− mice had substantially fewer BrdU-positive cells when compared with control mice ( Figure 2B ). To directly assess the necessity of Dek for tumor cell growth, cell lines were established from tumors isolated from independent mice. Dek expression was subsequently decreased by shRNA (Deksh) in Ron tg Dek +/+ derived tumors, and murine Dek (mDek) was exogenously expressed in cell lines generated from Ron tg Dek −/− tumors (see Western blots depicted as insets in Figure 2C) . In all cell lines tested, depleting Dek in Ron tg Dek +/+ cell lines decreased growth rates ( Figure 2C 
Dek expression positively correlates with breast cancer stem cell (BCSC) phenotypes
We have previously shown that DEK expression correlates with the size of the BCSC population in human MCF7 cells. 29 To test this finding in murine samples, we analyzed first passage cancer cells isolated from the Ron tg Dek +/+ and Ron tg Dek −/− tumors for known cell surface murine BCSC markers by flow cytometry (Lin − /CD49f + /CD24 + /CD44 low). [40] [41] [42] We detected significantly fewer Lin − /CD49f + /CD24 + /CD44 low cells in Ron tg Dek −/− tumors compared to Ron tg Dek +/+ samples ( Figure 2D ). To further our analysis, we plated Ron tg Dek +/+ R7 NTsh/Deksh cells and four Ron tg Dek −/− lines with empty vector or mDek for mammosphere formation. Although there were no differences in mammosphere numbers, a significant positive correlation between Dek expression and sphere volume was observed, which is in agreement with the notion that Dek drives proliferation ( Figure 2E 
Dek expression promotes cancer metastasis in vivo and in vitro
Previous reports using in vitro transwell assays suggests that DEK conferred invasive potential to breast cancer cells via a β-catenin-dependent mechanism. 29 Figure 3A ). Lung metastases were positive for cytokeratin 5 staining, indicating they were epithelial in origin ( Figure S3A ). One potential mechanism of metastasis is through the expression of matrix metalloproteases (MMPs), including the Wnt targets MMP2 and MMP9. 43 Primary tumors and the cell lines showed no correlation between DEK expression and matrix metalloprotease (MMP)-2 or MMP-9 expression ( Figure S3B and C). To test invasion in vitro, Dek proficient and deficient cell lines (described above) were analyzed using Matrigel transwell invasion assays. Dek expression enhanced the invasive potential in all cell lines tested ( Figure 3B , see Figures 2C and 4A for Dek expression).
Dek drives proliferation through Wnt signaling
We previously showed that DEK expression correlated with β-catenin activity in human breast cancer cell lines and that this activity drove cell invasion in Matrigel transwell assays. 29 However, the mechanism for this regulation was unknown. Preliminary data from a quantitative RT-PCR array was utilized wherein we screened for expression differences of over 80 Wnt signaling pathway members in Dek +/+ versus Dek −/− mouse embryonic fibroblasts 13 in order to select relevant Wnt/β-catenin pathway members for further analysis ( Figure S4A -B). We identified Wnt4, Wnt7b, and Wnt10b to be differentially regulated by Dek expression ( Figure 4A ). Dek shRNA in R7 cells resulted in decreased Wnt expression whereas complementation of four Ron tg Dek −/− cell lines with mDek resulted in increased Wnt expression. Wnt10b, a canonical Wnt ligand, was pursued due to its strong association with breast cancer development and proliferation. 44, 45 The observed differences in Wnt10b mRNA correlated with differences in secreted protein levels detected in conditioned media ( Figure 4B ). The upregulation of Wnts also correlated with increased β-catenin transcriptional activity as determined by the TOP/FOP luciferase reporter assay ( Figure 4C ), a finding which agrees with our previous work with mouse embryonic fibroblasts. 29 We also observed up-regulation of the pro-proliferative Wnt/β-catenin target gene cyclin D1 and increased protein levels of other Wnt pathway members ( Figure 4D Dek and Wnt expression, decreasing the proliferation of parental Dek-deficient RD147 cells close to control levels ( Figure 4E ).
Dek expression correlates with xenograft tumor growth, Wnt10b expression, and β-catenin activity in vivo
To determine if Dek regulates Wnt10b expression in vivo, Ron tg Dek +/+ R7 cells transduced with NTsh or Deksh constructs were injected into the mammary gland to generate orthotopic tumors in female nude mice. Tumors from Deksh cells grew significantly slower than tumors from control (NTsh) cells ( Figure 5A ). Immunohistochemical staining demonstrated significantly diminished Wnt10b and activated β-catenin levels in Deksh tumors, suggesting attenuated β-catenin activity ( Figure 5B , quantified in 5C). Together, this suggests that Dekmediated tumor growth is associated with Wnt expression and subsequent β-catenin activation.
RON receptor activation increases DEK expression and DEK over-expression confers tumorigenic phenotypes to immortalized human mammary epithelial cells
We treated T47D cells with HGFL to determine if RON activation also up-regulates DEK in human breast cancer cell lines. DEK mRNA was up-regulated within hours of HGFL stimulation, resulting in elevated protein levels ( Figure 6A -B) . This further supports the hypothesis that DEK over-expression in breast cancer cell lines is induced by RON receptor activation.
To determine if DEK over-expression promoted tumorigenic phenotypes in human mammary cells similar to that observed in the mouse, we used 3D cultures of MCF10A immortalized human mammary epithelial cells transduced with control R780 vector or R780:DEK. 29 This 3D human cell culture model closely mimics the structure of the mammary gland, with a spherical layer of polarized epithelium and a hollow lumen. 46 DEK over-expression resulted in a hyperplastic phenotype, as evident by the enlarged acinar structures and filled lumens ( Figure 6C , top and center panels). Wnt signaling is known to regulate cell and tissue polarity. [47] [48] [49] Therefore, we assessed polarity in this threedimensional context by staining for the apical surface marker, GM130. DEK overexpressing acini contained more cells with de-regulated polarity, as indicated by aberrant localization of GM130 ( Figure 6C , top panel, white arrows and graph below). When the acini were cultured in a mix of Matrigel and collagen to promote invasive phenotypes, DEK over-expression led to the production of invasive laminin-V negative multi-cellular structures, which were not observed in control cells ( Figure 6C , bottom panel and data not shown).
RON and DEK expression cooperate to promote β-catenin activity and disease progression in human primary breast cancers
Immunohistochemical staining of serial sections from two breast cancer microarrays was performed. Analyses were limited to infiltrating ductal carcinomas, and we determined that 54% (15 of 28) of samples expressed high levels of DEK while 46% (13 of 28) highly expressed RON. By themselves, the expression of each protein was suggestive of high β-catenin levels, indicating pathway activation ( Figure S5A ). When combined, 74% (31 of 42) of breast cancers expressed high levels of RON and/or DEK, which also was highly predictive of strong β-catenin staining ( Figure 6D ).
Finally, an in silico meta-analysis of patient and gene expression data archived in KaplanMeier Plotter (www.kmplot.com) was performed to assess the impact of DEK and RON expression on patient survival. In each case, high DEK expression was very predictive of poor patient outcome, the strength of the association was enhanced by adding RON expression ( Figure S5B-D) . Together, high DEK and RON expression were predictive of early relapse in breast cancer patients that did not receive systemic endocrine therapy or chemotherapy ( Figure 6E ). The combined markers also correlated with a higher risk for developing distant metastases in breast cancer patients treated with systemic therapies ( Figure 6F ) and with poor post-progression survival in all patients ( Figure S5D ).
Our results lead to a proposed model whereby elevated DEK expression results in the enhanced transcription and secretion of Wnt ligands that can promote cellular proliferation through a paracrine mechanism that is driven by β-catenin signaling ( Figure 7 ). Furthermore, RON receptor tyrosine kinase activation is a novel mechanism for DEK up-regulation and, independently, can promote β-catenin stabilization and subsequent transcriptional activity ( Figure 7 ). 6 This combination of events converging upon the β-catenin pathway can then contribute to tumor growth and metastasis.
Discussion
We previously published that Dek −/− mice developed fewer papillomas and were delayed in papilloma formation in a chemically-induced model of skin cancer. 30 We provide the first report of the role of the DEK oncogene in a genetic murine model of malignant breast cancer. In this report, the absence of Dek did not prevent tumor formation and the mice ultimately developed similar numbers of tumors. However, Dek −/− mice show delayed tumor initiation and have significantly fewer proliferating cells in pre-neoplastic mammary glands. This is supported by the finding that proliferation could be rescued by exogenous Dek expression in independently generated cell lines from these Dek −/− tumors. Importantly, we also have observed the relationship between Dek expression and cell growth in an esophageal cancer cell line derived from a murine 4NQO chemical carcinogenesis model, indicating that this correlation is not limited to the MMTV-Ron model ( Figure S6A ).
In human cancers, RNAi-mediated DEK loss has been reported to cause apoptosis or senescence, as well as decreased proliferation in the surviving cells. 29, 32, 34, 35, 50 Factors that determine the cellular response to DEK depletion are poorly understood, although p53, MCL-1, and p65 functionality have been implicated. 18, 27, 50 The fact that Dek knockout mice are viable seems to be at odds with the findings in human cells. However, differentiated human keratinocytes are largely resistant to apoptosis and senescence after DEK depletion by shRNA expression. This suggests that the differentiated, largely quiescent tissues in the mouse may not be dramatically affected by the loss of Dek under controlled stress and pathogen-free conditions. It is of interest that mouse embryonic fibroblasts (MEFs) from Dek −/− mice are slightly less proliferative with elevated numbers of senescent cells under normal culture conditions compared to Dek +/+ MEFs, possibly due to increased baseline levels of DNA damage. However, knockout MEFs are significantly more senescent and apoptotic when stressed, such as treatment with etoposide. 13 Therefore, we hypothesize that Dek/DEK expression promotes proliferation through Wnt signaling and ΔNp63 levels; however, the loss of Dek causes decreased mitogenic signaling as well as DNA damage which, when exacerbated by environmental stress and/or genetic background, leads to a dramatic apoptotic or senescent response. 13, 29, 37 Molecular mechanism(s) through which DEK promotes proliferation are not well understood. Cell-free assays and immunoprecipitation experiments suggest that DEK may facilitate DNA replication. 9, 14 DEK also promotes proliferation through ΔNp63 protein activities, but the effectors of this pathway remains unexplored. 29, 51, 52 Our previous studies have shown that DEK expression correlates with proliferation by BrdU incorporation in xenograft tumors and organotypic raft cultures of skin, but the molecular drivers behind this finding were not identified. 29, 52 We also published previously that DEK expression correlates with β-catenin activity in human breast cancer 29 and we have observed this correlation in primary cells from human head and neck squamous cell carcinomas (HNSCCs; Figure S6B -C), thus supporting broad importance for the observed DEK-β-catenin signaling axis in solid tumors. Here, we connect our previous findings and identify a molecular mechanism through which DEK can promote proliferation and β-catenin activity -through the transcriptional regulation of Wnt4, Wnt7b, and Wnt10b. These three Wnts have been implicated in promoting oncogenic phenotypes and proliferation. In particular, Wnt10b is a known canonical Wnt ligand that prompts the stabilization and activation of β-catenin and can promote proliferation in triple-negative breast cancer. 53 Wnt10b is an early marker of the mammary lineage, a crucial driver of mammary gland development, and supports mammary stem cell proliferation as suggested by regulation of mammary stem cell marker Sca-1. 44, 54, 55 Wnt10b also is over-expressed in breast cancer cell lines and can induce transformation; furthermore MMTV-Wnt10b mice develop hyperplasia and excessive ductal branching, phenotypes which precede the development of adenocarcinomas. 44, 45, 56 Wnt4 expression also supports basal mammary epithelial stem cell proliferation, promotes mammary gland development and branching during pregnancy, and is over-expressed in breast cancer cell lines, although it is not transforming by itself. [56] [57] [58] Wnt7b is a non-canonical ligand whose up-regulation has been observed in other murine breast cancer models and was shown to promote epithelial proliferation in the lung. [59] [60] [61] [62] [63] All three of these Wnts are known to be expressed in human breast tissue and were reported to be over-expressed in breast cancer. 64 Additional work will be required to determine whether Dek-mediated transcription of Wnt ligands is due to the role of DEK in chromatin re-organization or as a transcriptional co-factor. 15, 16 Furthermore, we report DEK-mediated positive regulation of β-catenin in both breast cancer and HNSCCs, which suggests that this oncogenic mechanism may be relevant for several types of solid tumors.
In co-culturing experiments we found that Dek-expressing cells could promote the proliferation of neighboring Dek-deficient cells through a paracrine signaling mechanism. Importantly, inhibiting the secretion of Wnt ligands with the Porcupine inhibitor, IWP-2, dramatically reduced this pro-proliferative effect. This suggests that Dek expressing cells promote the proliferation of cells within the tumor microenvironment. It is also noteworthy that IWP-2 did not entirely eliminate the pro-proliferative effect observed in co-culture experiments, indicating that Dek expressing cells may be secreting other growth factors that drive the proliferation of neighboring cells or cell intrinsic factors may continue to promote proliferation in the presence of the inhibitor. Interestingly, this may explain why DEK is not expressed in every cell in primary invasive breast adenocarcinomas; only a fraction of the cells may need to express DEK in order to drive proliferation of the entire tumor. 29 In addition, Wnt10b and Wnt4 drive mammary stem cell proliferation and Wnt/β-catenin activity is a well-known regulator of the normal and cancer stem cell populations. Future studies will determine if the positive effect of Dek expression on the size of the mouse and human breast cancer stem cell population is due to Wnt expression and β-catenin activation driving cancer stem cell proliferation.
This report highlights for the first time a role of Dek expression in an in vivo model of cancer metastasis. Although Dek loss did not prevent metastases, it significantly decreased metastatic tumor burden in the lungs and resulted in reduced liver metastases. We saw no correlation between Dek expression and the expression of Wnt target genes MMP2 and MMP9; however, this does not exclude other potential mechanisms. A possible alternative is that Dek may also regulate the expression of non-canonical Wnt ligands, like Wnt5a, which can activate the Rho/Rac planar cell polarity pathway to direct cell motility. 65, 66 Interestingly, DEK loss was recently shown to negatively regulate Rho signaling in nonsmall cell lung cancer. 67 In addition to lung metastases, we observed that Dek expression significantly promoted invasion in transwell assays in multiple murine breast cancer cell lines and in primary HNSCC cells ( Figure S6D ), which agrees with previous reports in human breast and lung cancer and indicates that DEK-mediated invasion is relevant to several cancer types. 29, 32 Of interest, breast patient data associated high DEK expression with an increased risk for distant metastasis in previously node-negative patients. The overall finding is that while Dek is not required for metastasis, it promotes cellular invasion and the growth of metastatic tumors. Interestingly, Wnt signaling has also been implicated in cellular motility and cancer metastasis. In canine breast adenocarcinomas, Wnt7b was found to be up-regulated in metastatic cell lines isolated from the lungs compared to isogenic primary tumor cell lines. 68 Wnt10b and Wnt4 are potent regulators of mammary gland branching, which leads us to hypothesize that they may be involved in DEK-mediated promotion of cancer cell motility when over-expressed in tumors. 44, 58 We have already reported that DEK knockdown decreased invasion in vitro in human breast cancer cells, and invasion was rescued by the expression of a constitutively active β-catenin construct. 29 This report, combined with our previous work, suggests that DEK-mediated activation of Wnt/β-catenin signaling, at least in part, promotes proliferation, invasion, and altered cell polarity. Although the signaling events regulated by RON and DEK are not fully understood, both are known to activate Wnt/β-catenin signaling. Both also have been implicated in promoting the activity of other oncogenic signaling cascades linked to cancer progression, including the roles of DEK in regulating the function of p53 family members and DNA repair and of RON in promoting the activation of PI3K-Akt and Ras/MAPK pathways. 13, 29, 52, 69 Combined, we propose that RON and DEK cooperate to drive breast cancer progression and relapse. Developing novel therapeutics that target these proteins could significantly slow tumor growth and limit the risk of metastasis or disease relapse, and may be particularly effective when combined with traditional therapies.
Materials and Methods
Cell Culture
T47D and MCF10A cells were obtained from the American Type Culture Collection and grown under recommended conditions. R7 cells are a murine mammary tumor line from a previously described MMTV-Ron mouse. 3, 39 We established the remaining cell lines from mammary tumors that developed in the MMTV-Ron (Ron tg ) mice used in this study. Cell lines R7, RD258, and RD272 were generated from Ron tg Dek +/+ tumors and cell lines RD147, RD219, RD238, and RD271 were from Ron tg Dek −/− tumors. Briefly, tumor fragments were digested in 2 mg/ml collagenase in DMEM:F12 media for two hours at 37°C then washed six times in PBS with differential centrifugation to enrich for epithelial cells.
Resulting organoids were grown in DMEM:F12 media supplemented with 10% FBS, 1% penicillin-streptomycin, 1% Fungizone, 2 mM L-glutamine, 5 μg/ml gentamicin, 10 ng/ml EGF, 10 μg/ml human recombinant insulin, 5 μg/ml transferrin, and 50 μM sodium selenite then passaged at least 20 times.
Cells were treated with 100 ng/ml recombinant HGFL protein (MSP, Cys 672 Ala; R&D Systems, Minneapolis, MN) for the indicated time points. To inhibit Wnt secretion, cells were treated with 10 μM IWP-2 (Sigma-Aldrich, St. Louis, MO) for 24 hours prior to analysis. For growth curves, cells were plated at equal density of 50,000 cells per well in 6-well plates, trypsinized, and counted in triplicate using a hemocytometer.
Three dimensional (3D) MCF10A cultures were generated and stained by immunofluorescence as previously described. 46 MCF10A cells retrovirally transduced with R780 and R780:DEK also were previously described. 29 Acinar structures were photographed at day 4 for invasive cultures (Matrigel and collagen) at 100x total magnification. Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope; the white size bar represents 10μm.
Cells were transduced with retroviral constructs, R780 and R780:mDek containing a murine Dek construct, as described previously and sorted based on GFP expression 30 or transduced with the lentiviral pLKO.1 constructs (Deksh represents pLKO.1_DEK832 in the Mission library; Sigma Aldrich and was previously described as "DEKsh2" 29 ) and selected in 4 μg/ml puromycin. NTsh is a non-targeting control. All cell populations were analyzed within six passages of selection.
PCR
Total mRNA was isolated using Trizol extraction, then reverse transcribed using the Quantitect kit (Qiagen, Valencia, CA). cDNA was amplified with SYBR Green PCR master mix using an ABI-7500 quantitative PCR machine (Applied Biosystems, Carlsbad, CA) and analyzed using the ΔΔCt method. The following forward (F) and reverse (R) primer pairs were used at a concentration of 0.4 ng/μl each. Primers labeled with "m" were used for murine cells and those with an "h" denote human sequence. hDEK R-5′-ATTAAAGGTTCATCATCTGAACTATCCTC-3′
Western blotting
Total protein was extracted with RIPA buffer and subjected to SDS-PAGE analysis prior to transfer to a PVDF membrane. Blots were probed with specific antibodies to DEK (BD Bioscience, San Jose, CA); Ron (C-20), Wnt10b [H70], and cyclin D1 [72-13G] (Santa Cruz, Dallas, TX); alpha-tubulin (Sigma), Actin C4 (gift of James Lessard, Cincinnati Children's Hospital); Axin 2, MMP-2, and MMP-9 (Abcam, Cambridge, MA), cytokeratin 14 (Covance, Princeton, NJ), and GSK3β, phospho-ERK1/2, total ERK1/2, and TCF1 (Cell Signaling, Danvers, MA). Protein from primary mammary epithelial cells was collected from 18 week old nulliparous, non-tumor bearing Dek +/+ females by isolating the cells through collagenase digestion and differential centrifugation as described above immediately prior to the addition of lysis buffer. For secreted proteins, 3×10 6 cells were plated on 10cm dishes in complete media for 2 hours cells then washed in PBS and overlayed with media containing 1% FBS for 24 hours. Six milliliters of conditioned media was collected from each cell line and concentrated to 100 μl using Amicon Ultra-4 centrifugal filters with Ultracel-3 membrane (Millipore, Billerica, MA) then 2 μl was diluted into 18 μl of serum free media prior to western blotting. Western blots were analyzed by densitometry using Image J. For xenograft studies, 5×10 5 cells suspended in PBS were injected into the inguinal mammary fat pads of nulliparous, 12-week old female athymic nude mice. Tumors were measured and collected as described above. Usage and handling of mice was performed with the approval of the Cincinnati Children's Institutional Animal Care and Use Committee. All mice were housed in specific pathogen free housing with ad libitum access to food and water.
Immunohistochemistry
Paraformaldehyde fixed and paraffin embedded tissues were cut into 5 μm sections, subjected to sodium citrate antigen retrieval, and stained using the M.O. mm dishes, grown overnight, then treated with 100 μM BrdU for 35 minutes before staining with the APC BrdU kit (BD Biosciences). BrdU incorporation was measured in GFP− and GFP+ cells.
Mammosphere Culture
Mammosphere cultures were performed and photographed as previously described. 29 Image J was used to measure the radius and calculated sphere volume as (4/3)π*r 3 for each mammosphere in triplicate experiments.
Invasion Assay
Matrigel transwell assays were used to determine invasive potential in vitro (BD Biosciences). Cells were seeded at low density in supplement-free media and complete media was placed into the bottom chamber as a chemoattractant. After 20 hours, invading cells were methanol-fixed and stained with Giemsa then manually counted. The data is represented as fold change relative to vector controls.
TOP/FOP Assay
Cells were transfected with 10 ng pRL-TK and 500ng of pSUPER(8x)TOPFlash or pSUPER(8x)FOPFlash using TransIT-LT1 reagent (Mirus Bio, Madison, WI) then assayed with the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). Plasmids were a gift from Dr. Aaron Zorn (Cincinnati Children's Hospital). Data is presented as the ratio of relative light units (RLUs) of TOPFlash to FOPFlash from triplicate experiments.
Kaplan-Meier Curves
Kaplan Meier plots were generated with KM plotter for Breast Cancer, 2014 version (www.kmplot.com), which is a publicly available online database of archived gene expression and patient survival data. 74 We used the multigene classifier and mean expression of probes, 200934_at (DEK) and 205455_at (RON), and did not restrict analysis by subtype. We analyzed relapse free survival (RFS) in systemically untreated patients and distant metastasis free survival (DMFS) in patients treated with endocrine therapies or chemotherapies.
Statistics
Mouse tumor-free survival was analyzed using the Log-rank test. The χ 2 test was used to identify correlations with protein expression using tissue microarrays. For all other experiments, an unpaired two-tailed Student's t-test was used, unless otherwise noted. Error bars depict standard error of data collected from at least three experiments. Significance was set at p<0.05. One asterisk (*) indicates p<0.05, two asterisks (**) indicates p<0.01, and three asterisks (***) indicates p<0.001. Ron stimulates Dek expression for sustained β-catenin signaling. Ron can directly activate intracellular β-catenin while Dek induces expression of Wnt ligands which are secreted into the tumor microenvironment to amplify β-catenin activity by autocrine and paracrine mechanisms.
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